Literature DB >> 7548000

Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.

M Ploug1, H Rahbek-Nielsen, V Ellis, P Roepstorff, K Danø.   

Abstract

The high-affinity interaction between urokinase-type plasminogen activator (uPA) and its glycolipid anchored receptor (uPAR) is essential for the confinement of plasminogen activation to cell surfaces where it is thought to play an important role in cancer cell invasion and metastasis. The receptor binding site of uPA is retained within its isolated growth factor-like module (GFD; residues 4-43). The NH2-terminal domain of uPAR has a primary role in uPA binding, although maintenance of its multidomain structure has been shown to be necessary for the high affinity of this interaction [Ploug, M., Ellis, V., & Danø, K. (1994) Biochemistry 33, 8991-8997]. To identify residues engaged in the uPAR-uPA interaction, we have performed a "protein-protein footprinting" study on preformed uPAR-GFD complexes by chemical modification with tetranitromethane. All six tyrosine residues in uPAR and the single tyrosine residue in GFD (Tyr24) were susceptible to nitration in the native uncomplexed proteins, whereas in the receptor-ligand complexes both Tyr57 of uPAR and Tyr24 of GFD were protected from modification. Modification of uPAR alone led to a parallel reduction in the potential to bind pro-uPA and 8-anilino-1-naphthalenesulfonate, an extrinsic fluorophore reporting on the accessibility of a hydrophobic site involved in uPA binding. These data clearly demonstrate that Tyr57 in the NH2-terminal domain of uPAR and Tyr24 in uPA are intimately engaged in the receptor-ligand interaction, whereas Tyr87 positioned in the linker region between the first two domains of uPAR does not appear to be shielded by the resulting intermolecular interface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548000     DOI: 10.1021/bi00039a006

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

Review 2.  Probing protein structure by amino acid-specific covalent labeling and mass spectrometry.

Authors:  Vanessa Leah Mendoza; Richard W Vachet
Journal:  Mass Spectrom Rev       Date:  2009 Sep-Oct       Impact factor: 10.946

3.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Authors:  Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Journal:  EMBO J       Date:  2005-04-07       Impact factor: 11.598

Review 4.  Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications.

Authors:  Xiaoran Roger Liu; Mengru Mira Zhang; Michael L Gross
Journal:  Chem Rev       Date:  2020-04-22       Impact factor: 60.622

Review 5.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

6.  Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.

Authors:  Henrik Gårdsvoll; Benedikte Jacobsen; Mette C Kriegbaum; Niels Behrendt; Lars Engelholm; Søren Østergaard; Michael Ploug
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

7.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

8.  Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.

Authors:  G Høyer-Hansen; U Pessara; A Holm; J Pass; U Weidle; K Danø; N Behrendt
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

9.  Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.

Authors:  Anastasia M Makarova; Tatiana V Lebedeva; Taher Nassar; Abd Al-Roof Higazi; Jing Xue; Maria E Carinato; Khalil Bdeir; Douglas B Cines; Victoria Stepanova
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

Review 10.  Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.

Authors:  Michael Ploug
Journal:  Theranostics       Date:  2013-06-24       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.